On Mar. 23, 2021, Omeros and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial had begun. The I-SPY COVID-19 Trial was an adaptive platform trial that was to screen rapidly, in parallel, multiple promising agents in order to identify drugs that have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.